Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Author information

1
Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: sarah.holstein@unmc.edu.
2
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
3
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
4
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, North Carolina.
5
US Food and Drug Administration, Silver Spring, Maryland.
6
The Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
7
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
8
Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
9
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Boston, Massachusetts.
10
Division of Hematology, Myeloma Unit, University of Torino, Torino, Italy.
11
Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, Leeds, United Kingdom.
12
Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
13
Department of Hematology, Universit Hospital of Salamanca, Salamanca, Spain.
14
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
15
Department of Hematology, Oncology, Immunology and Rheumatology, Universitatsklinikum Tubingen, Tubingen, Germany.

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

KEYWORDS:

Autologous stem cell transplantation; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma

PMID:
30408566
PMCID:
PMC6445685
[Available on 2020-03-01]
DOI:
10.1016/j.bbmt.2018.11.001

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center